Clinical Trial Update: Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2a dose-finding and PK/PD study of ANAVEX2-73 in Alzheimer's disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ANAVEX2-73 (blarcamesine)

Snippet

Sponsor: Anavex Life Sciences Corp. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED